AGL Resources Inc. (NYSE:GAS) shares advanced 0.17% in last trading session and ended the day at $63.11. GAS Gross Margin is 53.20% and its has a return on assets of 2.80%. AGL Resources Inc. (NYSE:GAS) quarterly performance is 4.47%.
On 7 December, AGL Resources Inc. (NYSE:GAS) and Southern Company (NYSE: SO) announced the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (“HSR Act”) has expired with regard to the companies’ proposed merger. One of the conditions to the merger is that the waiting period under the HSR Act has expired.
Opexa Therapeutics, Inc. (NASDAQ:OPXA) ended the last trading day at $2.98. Company weekly volatility is calculated as 5.13% and price to cash ratio as 1.31. Opexa Therapeutics, Inc. (NASDAQ:OPXA) showed a weekly performance of -1.97%.
Research analysts at Aegis assumed coverage on shares of Opexa Therapeutics, Inc. (NASDAQ:OPXA) in a research note issued to investors on Thursday, Analyst Ratings Network.comreports. The firm set a “buy” rating on the biopharmaceutical company’s stock.
On 15 December, EQT Corporation (NYSE:EQT) shares advanced 0.48% and was closed at $48.30. EQT EPS growth in last 5 year was 16.30%. EQT Corporation (NYSE:EQT) year to date (YTD) performance is -36.10%.
On 3 December, EQT Corporation (NYSE:EQT) announced the realignment of certain executive responsibilities, which includes the appointment of Steven T. Schlotterbeck as President of EQT Corporation (EQT or Company). Schlotterbeck will also retain his title of President, Exploration and Production; and David L. Porges will remain Chairman and Chief Executive Officer of EQT.
Advanced Semiconductor Engineering Inc. (NYSE:ASX) shares advanced 5.79% in last trading session and ended the day at $5.48. ASX Gross Margin is 19.60% and its has a return on assets of 7.20%.
Advanced Semiconductor Engineering Inc. (NYSE:ASX) announced that its board of directors has approved and submitted a proposal (the “Proposal”) to Siliconware Precision Industries Co., Ltd. (Nasdaq: SPIL) to acquire all SPIL shares for cash, to be effected through an agreed statutory share exchange transaction under Taiwan law between ASE and SPIL on customary terms and conditions.
Puma Biotechnology, Inc. (NYSE:PBYI) caters to the Healthcare space. Its weekly performance is -6.30%. On the last day of trading company shares ended up at $75.42. Puma Biotechnology, Inc. (NYSE:PBYI) distance from 50-day simple moving average (SMA50) is -4.87%.
On 10 December, Puma Biotechnology, Inc. (NYSE:PBYI) announced that interim results from an ongoing Phase II clinical trial of Puma’s investigational drug PB272 (neratinib) were presented at the 2015 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas.
Leave a Reply